MOTS-c

1. What is it?

MOTS-c consists of 16 amino acids, and the information needed to produce it is found in mitochondrial genetic material. Mitochondria are parts of cells important for energy use. Researchers study the peptide's role in communication about the body's energy state. Its natural presence does not establish the safety of an externally administered preparation. The body's own regulation and supplying additional substance are different biological situations. [167]

2. Why do people turn to it?

MOTS-c attracts people interested in physical performance, weight loss and staying healthy with age. Researchers study glucose control, obesity and responses to exercise. Experiments in mice have produced findings that encourage further work. However, they do not establish a diabetes treatment, a way to improve human endurance or a method of extending life. Each use would require separate evidence of a real benefit in humans, how long it lasts and any health costs. [167] [168]

3. How does it work?

MOTS-c may affect pathways through which cells respond to energy availability, including the system known as AMPK. This forms part of the regulation of how cells use fuel. Activating such a pathway is not equivalent to improving a person's overall fitness. Similar signals can have different consequences in different tissues and conditions. Measures of cell activity must therefore be distinguished from outcomes such as physical functioning or fewer illnesses. [167] [169]

4. What do studies actually show?

A 2015 paper mainly reported experiments on cells and mice studying metabolism. A 2021 publication also examined changes in natural MOTS-c during exercise in 10 healthy young men. Participants in this part of the study were not given the peptide as a treatment. Observing the body's response to exercise therefore does not show that externally supplied MOTS-c can replace training. Experiments that administered the substance and assessed physical performance involved mice. The human part shows the body's response to exercise, while the animal part examines the effects of giving the peptide. Combining these experiments without making this distinction can create a misleading impression of an established treatment. [167] [168]

5. What do we still not know?

The level of a natural substance can change with exercise, disease or age, but an association alone does not explain the cause. It does not tell us whether increasing that level would improve health. Findings in young, healthy men also cannot be extended to older people with several conditions. Studies need to assess administration of a specific product and outcomes that matter to patients, with sufficiently long follow-up. [168] [170]

6. What are the risks?

In its 2026 assessment, the FDA notes insufficient data to describe the safety of MOTS-c in humans. This includes a full toxicity assessment and possible problems related to peptide quality. The varied effects observed in cells provide another reason for caution. It is not currently possible to make a reliable promise that the substance will increase energy without other consequences. A lack of complication data should not be presented as a favourable safety-study finding. [170] [169]

In sport governed by WADA anti-doping rules, this substance is prohibited at all times, including outside competition. The 2026 list names it explicitly. Use during training or a break between competitions is also covered by the ban. [193]

7. Is it an approved medicine?

MOTS-c remains investigational and, in the cited FDA assessment, is not an ingredient in a US-approved medicine. There is no basis for presenting it as an approved weight-loss or anti-ageing treatment in Poland. Discussions about compounding ingredients and a new trial-register entry do not approve an effective therapy. [170]

8. What is new in research?

A study of human cells derived from fat tissue was published in June 2026. MOTS-c stimulated metabolic signals but, under some conditions, reduced the cells' repair abilities; using them in a mouse model did not produce the expected improvement in kidney repair. This was not a trial administering MOTS-c to humans. The paper does not demonstrate clinical harm, but shows that broad claims about regeneration go too far. [169]

Where does this information come from?

References link to the publications and documents used. Each source includes its material type and what was reviewed; findings concern the substance, form and study population described.